Four cases of red blood cell aplasia in association with the use of mycophenolate mofetil in renal transplant patients

Treatment of Pure Red-Cell Aplasia With Cyclosporine in a Renal Transplant Patient

“…Emergence of mycophenolate mofetil-related PRCA has been seen in the early posttransplant period and also, hematologic improvement has been seen immediately after ceasing mycophenolate mofetil in some case reports and in solid-organ transplant series. 2,3 In our case, although severe anemia occurred immediately postoperatively, cessation of mycophenolate mofetil did not result in recovery of the patient. The effectiveness of cyclosporine in treating PRCA is 65% to 87%.…”

“…A response to autoimmune PRCA has been obtained with various immunosuppressive regimens including corticosteroids, cyclosporine, azathioprine, alkylation agents, or anti-thymocyte globulin, tacrolimus, and intravenous immunoglobulin. 1,3,5 Mycophenolate mofetil is used in immune suppressive therapy in adult or childhood allogenic renal, cardiac, or hepatic transplant patients in combination with corticosteroids and cyclosporine. 6 Pure red cell aplasia related to mycophenolate mofetil therapy has been reported in 41 cases with 18 of them achieving normal hemoglobulin levels with either cessation or escalation of mycophenolate mofetil dosage.…”

“…Laboratory findings were hemoglobulin 46 g/L, leukocyte count 7.5 × 10 9 /L, platelet count 429 × 10 9 /L, reticulocyte 0. Puren Gokbulut, 3 Bulent Aydinli biochemical evaluation for vitamin B12 and iron deficiency were normal. The results of a bone marrow examination showed a prominent decrease in the erythroid series ( Figure 1).…”

“…1 There have been reports of PRCA after immune suppression with tacrolimus and mycophenolate mofetil in transplanted patients. [2][3][4] We present a deceased-donor renal transplant patient who developed PRCA, which was caused by either mycophenolate mofetil or tacrolimus and treated with cyclosporine.…”

Aplasia medular tratada exitosamente con ciclosporina en un paciente en hemodiálisis crónica

“…Si bien en los primeros meses del trasplante renal hubo un deterioro en el recuento de plaquetas y anemia, éstos se revirtieron a los cuatro meses sin modificar la terapia. Es posible que el empleo del micofenolato pueda haber tenido un efecto frenador sobre la médula ósea especialmente durante el período en que la función renal no se había recuperado 20 .…”